Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vinci SA
OTC:VCISF
|
FR |
|
Q
|
Questcorp Mining Inc
OTC:QQCMF
|
CA |
|
Genting Bhd
OTC:GEBEY
|
MY |
|
C
|
Cleen Energy AG
VSE:CLEN
|
AT |
|
Lion Metal Works Tbk PT
IDX:LION
|
ID |
|
Coca-Cola Bottlers Japan Holdings Inc
OTC:CCOJY
|
JP |
|
Superior Group of Companies Inc
NASDAQ:SGC
|
US |
|
J
|
Jindal Stainless Ltd
BSE:532508
|
IN |
|
Hospital Mater Dei SA
BOVESPA:MATD3
|
BR |
|
Australian Vintage Ltd
ASX:AVG
|
AU |
Arbutus Biopharma Corp
Total Equity
Arbutus Biopharma Corp
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Total Equity
$76.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
See Also
What is Arbutus Biopharma Corp's Total Equity?
Total Equity
76.6m
USD
Based on the financial report for Dec 31, 2025, Arbutus Biopharma Corp's Total Equity amounts to 76.6m USD.
What is Arbutus Biopharma Corp's Total Equity growth rate?
Total Equity CAGR 10Y
-18%
Over the last year, the Total Equity growth was -21%. The average annual Total Equity growth rates for Arbutus Biopharma Corp have been -18% over the past three years , -6% over the past five years , and -18% over the past ten years .
